The British pharmaceutical giant Glaxo Wellcome has got itself entangled in another suit ( Down To Earth , Vol 5, No 6). This time, the fight is against Emory University of Atlanta, US, over the patent on its AIDS drug, Epivir, also known as 3TC. The drug had been patented in 1991 by a Canadian firm BioChem Pharma, which had originally developed the drug before striking a partnership deal with Glaxo. Emory was granted a US patent for Epivir last month. BioChem claimed that it had developed its 3TC process independently of the work done by Emory researchers and obtained a patent first.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
.png)
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.